|
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
|
20 August 2019 |
|
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
|
14 August 2019 |
|
Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease
|
20 June 2019 |
|
New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
|
22 May 2019 |
|
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer
|
08 May 2019 |
|
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery
|
30 April 2019 |
|
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
|
02 April 2019 |
|
Forxiga approved in Japan for type-1 diabetes
|
27 March 2019 |
|
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
|
18 March 2019 |
|
Brilinta’s Phase III THEMIS trial met primary endpoint in
patients with established coronary artery disease and type-2 diabetes
|
25 February 2019 |